Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R).
{{Infobox drug | drug_name = | INN = | type = | image = Pexidartinib.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Turalio | Drugs.com = | MedlinePlus = a619050 | licence_CA = | licence_EU = | DailyMedID = Pexidartinib | licence_US = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = EX15
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).